PL3805243T3 - Pochodne androstanowe posiadające aktywność jako czyste lub w przeważającym stopniu czyste stymulatory SERCA2A do leczenia niewydolności serca - Google Patents
Pochodne androstanowe posiadające aktywność jako czyste lub w przeważającym stopniu czyste stymulatory SERCA2A do leczenia niewydolności sercaInfo
- Publication number
- PL3805243T3 PL3805243T3 PL19202257.2T PL19202257T PL3805243T3 PL 3805243 T3 PL3805243 T3 PL 3805243T3 PL 19202257 T PL19202257 T PL 19202257T PL 3805243 T3 PL3805243 T3 PL 3805243T3
- Authority
- PL
- Poland
- Prior art keywords
- pure
- serca2a
- stimulators
- activity
- treatment
- Prior art date
Links
- 206010019280 Heart failures Diseases 0.000 title 1
- 150000001440 androstane derivatives Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0038—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 with an androstane skeleton, including 18- or 19-substituted derivatives, 18-nor derivatives and also derivatives where position 17-beta is substituted by a carbon atom not directly bonded to a further carbon atom and not being part of an amide group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0088—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing unsubstituted amino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
- C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J21/005—Ketals
- C07J21/008—Ketals at position 17
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Cardiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19202257.2A EP3805243B1 (en) | 2019-10-09 | 2019-10-09 | Androstane derivatives with activity as pure or predominantly pure stimulators of serca2a for the treatment of heart failure |
Publications (1)
Publication Number | Publication Date |
---|---|
PL3805243T3 true PL3805243T3 (pl) | 2024-03-18 |
Family
ID=68242483
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL19202257.2T PL3805243T3 (pl) | 2019-10-09 | 2019-10-09 | Pochodne androstanowe posiadające aktywność jako czyste lub w przeważającym stopniu czyste stymulatory SERCA2A do leczenia niewydolności serca |
Country Status (16)
Country | Link |
---|---|
US (1) | US20230009312A1 (pl) |
EP (1) | EP3805243B1 (pl) |
JP (1) | JP2022551165A (pl) |
KR (1) | KR20220079601A (pl) |
CN (1) | CN114466855A (pl) |
AU (1) | AU2020363865A1 (pl) |
BR (1) | BR112022003915A2 (pl) |
CA (1) | CA3149938A1 (pl) |
DK (1) | DK3805243T3 (pl) |
ES (1) | ES2970792T3 (pl) |
FI (1) | FI3805243T3 (pl) |
IL (1) | IL291412A (pl) |
MX (1) | MX2022003997A (pl) |
PL (1) | PL3805243T3 (pl) |
TW (1) | TW202128182A (pl) |
WO (1) | WO2021069570A1 (pl) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114409726B (zh) * | 2022-01-24 | 2023-07-04 | 东华大学 | 桦木醇环烯烃衍生物及其用途和制备方法 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1175219A (en) * | 1967-06-22 | 1969-12-23 | Ici Ltd | 3-Aminoalkoxycarbonylmethylene Steroid Derivatives |
US4534899A (en) | 1981-07-20 | 1985-08-13 | Lipid Specialties, Inc. | Synthetic phospholipid compounds |
DE3485647D1 (de) * | 1983-08-02 | 1992-05-21 | Research Corp | Steroide und diese enthaltende therapeutische zusammensetzungen. |
US5225183A (en) | 1988-12-06 | 1993-07-06 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
US6509006B1 (en) | 1992-07-08 | 2003-01-21 | Inhale Therapeutic Systems, Inc. | Devices compositions and methods for the pulmonary delivery of aerosolized medicaments |
US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
US6051256A (en) | 1994-03-07 | 2000-04-18 | Inhale Therapeutic Systems | Dispersible macromolecule compositions and methods for their preparation and use |
US5846743A (en) | 1995-02-22 | 1998-12-08 | Brigham And Women's Hospital, Inc. | Polyphoshoinositide binding peptides for intracellular drug delivery |
KR19980703876A (ko) | 1995-04-14 | 1998-12-05 | 스티븐 엘. 허스트 | 분산성이 개선된 분말화된 약학적 조성물 |
US5716928A (en) | 1995-06-07 | 1998-02-10 | Avmax, Inc. | Use of essential oils to increase bioavailability of oral pharmaceutical compounds |
US5858401A (en) | 1996-01-22 | 1999-01-12 | Sidmak Laboratories, Inc. | Pharmaceutical composition for cyclosporines |
US6007839A (en) | 1996-02-16 | 1999-12-28 | The Liposome Company, Inc. | Preparation of pharmaceutical compositions containing etherlipid-containing multiple lipid liposomes |
DE19633349A1 (de) | 1996-08-19 | 1998-02-26 | Sigma Tau Ind Farmaceuti | Neue 6-Hydroxy- und 6-Oxo-androstan-Derivate, die auf das kardiovaskuläre System wirken und pharmazeutische Zusammensetzungen, die diese enthalten |
US5874268A (en) | 1996-09-23 | 1999-02-23 | Duke University | Method of introducing exogenous compounds into cells by electroporation and apparatus for same |
US6630137B1 (en) | 1997-04-28 | 2003-10-07 | Eli Lilly And Company | Activated protein C formulations |
AU8285998A (en) | 1997-07-02 | 1999-01-25 | Sdg, Inc. | Targeted liposomal constructs for diagnostic and therapeutic uses |
SE9704076D0 (sv) | 1997-11-06 | 1997-11-06 | Holdingbolaget Vid Goeteborgs | Method for permeabilisation of cell structures and use thereof |
US6589503B1 (en) | 1998-06-20 | 2003-07-08 | Washington University | Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy |
US20040151766A1 (en) | 2003-01-30 | 2004-08-05 | Monahan Sean D. | Protein and peptide delivery to mammalian cells in vitro |
US20050136121A1 (en) | 2003-12-22 | 2005-06-23 | Shear/Kershman Laboratories, Inc. | Oral peptide delivery system with improved bioavailability |
KR20060123384A (ko) | 2003-12-24 | 2006-12-01 | 가부시키가이샤 엘티티 바이오파마 | 약물을 함유하는 나노 입자 및 그 제조 방법, 그리고 당해나노 입자로 이루어지는 비경구 투여용 제제 |
US8658203B2 (en) | 2004-05-03 | 2014-02-25 | Merrimack Pharmaceuticals, Inc. | Liposomes useful for drug delivery to the brain |
US20070082042A1 (en) | 2004-08-06 | 2007-04-12 | Deok-Hoon Park | Multiple-layered liposome and preparation method thereof |
DE602005025676D1 (de) | 2004-10-18 | 2011-02-10 | Nitto Denko Corp | Intrazelluläre peptidabgabe |
EP1937213B1 (en) | 2005-07-27 | 2017-10-25 | Protiva Biotherapeutics Inc. | Systems and methods for manufacturing liposomes |
CA2641303C (en) * | 2006-01-31 | 2013-05-14 | The University Of Toledo | Na/k-atpase ligand |
TWI392682B (zh) * | 2006-04-13 | 2013-04-11 | Sigma Tau Ind Farmaceuti | 作為心血管疾病的治療藥物之雄甾烷和雄甾烯的胺基衍生物 |
TWI389917B (zh) * | 2006-04-13 | 2013-03-21 | Sigma Tau Ind Farmaceuti | 作為心血管疾病治療藥物的雄甾烷與雄甾烯之氮雜環烷基衍生物 |
PL2411015T3 (pl) * | 2009-03-23 | 2016-05-31 | Cvie Therapeutics Ltd | Pochodne 5-beta,14-beta-androstanu przydatne w leczeniu białkomoczu, stwardnienia kłębków nerkowych i niewydolności nerek |
WO2014018375A1 (en) * | 2012-07-23 | 2014-01-30 | Xenon Pharmaceuticals Inc. | Cyp8b1 and uses thereof in therapeutic and diagnostic methods |
KR20210136048A (ko) * | 2019-03-05 | 2021-11-16 | 윈드트리 세라퓨틱스, 인크. | 급성 심부전 (ahf)의 치료를 위한 이스타록심-함유 정맥내 제형 |
-
2019
- 2019-10-09 ES ES19202257T patent/ES2970792T3/es active Active
- 2019-10-09 FI FIEP19202257.2T patent/FI3805243T3/fi active
- 2019-10-09 DK DK19202257.2T patent/DK3805243T3/da active
- 2019-10-09 PL PL19202257.2T patent/PL3805243T3/pl unknown
- 2019-10-09 EP EP19202257.2A patent/EP3805243B1/en active Active
-
2020
- 2020-10-08 CA CA3149938A patent/CA3149938A1/en active Pending
- 2020-10-08 WO PCT/EP2020/078253 patent/WO2021069570A1/en active Application Filing
- 2020-10-08 JP JP2022521426A patent/JP2022551165A/ja active Pending
- 2020-10-08 MX MX2022003997A patent/MX2022003997A/es unknown
- 2020-10-08 BR BR112022003915A patent/BR112022003915A2/pt unknown
- 2020-10-08 US US17/640,294 patent/US20230009312A1/en active Pending
- 2020-10-08 CN CN202080066971.XA patent/CN114466855A/zh active Pending
- 2020-10-08 TW TW109134997A patent/TW202128182A/zh unknown
- 2020-10-08 AU AU2020363865A patent/AU2020363865A1/en active Pending
- 2020-10-08 KR KR1020227014956A patent/KR20220079601A/ko unknown
-
2022
- 2022-03-16 IL IL291412A patent/IL291412A/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2021069570A1 (en) | 2021-04-15 |
EP3805243A1 (en) | 2021-04-14 |
EP3805243B1 (en) | 2023-11-15 |
IL291412A (en) | 2022-05-01 |
US20230009312A1 (en) | 2023-01-12 |
FI3805243T3 (fi) | 2024-02-07 |
KR20220079601A (ko) | 2022-06-13 |
TW202128182A (zh) | 2021-08-01 |
BR112022003915A2 (pt) | 2022-08-23 |
DK3805243T3 (da) | 2024-01-02 |
AU2020363865A1 (en) | 2022-02-24 |
CA3149938A1 (en) | 2021-04-15 |
JP2022551165A (ja) | 2022-12-07 |
MX2022003997A (es) | 2022-04-26 |
ES2970792T3 (es) | 2024-05-30 |
CN114466855A (zh) | 2022-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12015502794A1 (en) | Pyrimidinedione compounds against cardiac conditions | |
EP4234017A3 (en) | 4-methylsulfonyl-substituted piperidine urea compounds useful for the treatment of cardiac disorders such as dilated cardiomyopathy (dcm) | |
EP3242709A4 (en) | Cardiac stimulation of atrial-ventricle pathways and/or associated tissue | |
EP3038540A4 (en) | Cardiac tissue anchoring devices, methods, and systems for treatment of congestive heart failure and other conditions | |
WO2015191886A3 (en) | Systems and methods for treating cardiac arrhythmias | |
MX2018008709A (es) | Uso terapeutico de inhibidores de activacion o estimulacion de celulas t. | |
EP3790563A4 (en) | COMPOSITION FOR THE TREATMENT OF SKIN CONDITIONS | |
EP3003452A4 (en) | Cardiac tissue penetrating devices, methods, and systems for treatment of congestive heart failure and other conditions | |
WO2014099633A3 (en) | Inhibitors of the renal outer medullary potassium channel | |
EP3906043A4 (en) | METHODS AND COMPOSITIONS FOR TREATING FABRY'S DISEASE | |
EP4025296A4 (en) | HEART PACING SYSTEM | |
MX2017016347A (es) | Terapia de combinacion de activador de miosina cardiaca e inhibidor de corriente if del nodo sinusal. | |
IL285921A (en) | Intravenous formulation including estrogens for the treatment of acute heart failure | |
IL291412A (en) | Androstane derivatives with activity as pure or mostly pure serca2a agonists for the treatment of heart failure | |
EP3813872A4 (en) | COMPOSITIONS FOR THE TREATMENT OF SKIN CONDITIONS | |
EP3585262A4 (en) | EMERGENCY HEART AND ELECTROCARDIOGRAM ELECTRODE PLACEMENT SYSTEM | |
EP3259346A4 (en) | P63 inactivation for the treatment of heart failure | |
IL277141A (en) | Compounds for the treatment of heart rhythm disturbances and heart failure | |
IL275273A (en) | An improved compound for the treatment of heart failure | |
GB2588904B (en) | Improvements in, or relating to, the treatment of by-products | |
WO2013079048A3 (de) | Implantierbare indifferente elektrode | |
EP3903878A4 (en) | INTRACARDIAL DEFIBRILLATION CATHETER SYSTEM | |
EP3612178A4 (en) | VASODILATERS FOR THE TREATMENT OF HEART FAILURE | |
EP3690054A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF HEART FAILURE | |
IL280243A (en) | Compounds similar to 17beta-heterocyclyl-digitalis for the treatment of heart failure |